CD47 and cancer: As part of the tumor mass, tumor-associated macrophages (TAM) are interesting therapeutic target based on data that have shown that the antiphagocytic protein CD47 is increased on the surface of cancer cells, allowing them to evade the innate immune system To avoid the interaction of CD47 with SIRP-α, it is used an anti-CD47 monoclonal antibody (mAb).